Harmony Biosciences Holdings, Inc. recently released its 10-K report, detailing its financial performance and business operations. The company, a commercial-stage pharmaceutical firm, is primarily focused on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. Its flagship product, WAKIX (pitolisant), is a novel treatment for excessive daytime sleepiness in adult patients with narcolepsy. Harmony Biosciences also has an extensive pipeline of products under development, including treatments for Prader-Willi Syndrome, Myotonic Dystrophy, Fragile X Syndrome, and other rare genetic disorders.
In the 10-K report, the company discussed its financial condition and results of operations, highlighting its focus on rare neurological diseases and its commitment to addressing unmet medical needs. The report also provided an overview of the company's recent developments and achievements, such as the acquisition of additional assets to expand its pipeline and the initiation of clinical trials for new formulations of pitolisant.
Harmony Biosciences reported continued growth in the number of healthcare professional prescribers of WAKIX, with approximately 8,500 patients on the medication as of December 31, 2025. The company also secured formulary access for more than 80% of all insured lives in the United States, including Commercial, Medicare, and Medicaid.
The 10-K report detailed the company's net product revenue, which includes gross product shipments less provisions for sales discounts and allowances. It also provided information on the company's pipeline products, such as EPX-100 for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome, and ZYN002 for the treatment of Fragile X Syndrome and 22q Deletion Syndrome.
As a result of these announcements, the company's shares have moved -0.52% on the market, and are now trading at a price of $36.22. Check out the company's full 10-K submission here.
